Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab dose comparison in mCRPC
NCT02279862Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of ipilimumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Bristol Myers Squibb. Started Dec 2014; status: completed.
02
Drugs
ipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02279862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279862.